Evidence map›Paper›PMID 31384528›Full record

ReviewActa pharmaceutica Sinica. B2019

Development of precision medicine approaches based on inter-individual variability of BCRP/

Liming Chen, Jose E Manautou, Theodore P Rasmussen, Xiao-Bo Zhong

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. How Cryo-EM Has Expanded Our Understanding of Membrane Transporters.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  18. Review
  19. ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives.International journal of molecular sciences · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Liming ChenDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.
Jose E ManautouDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.
Theodore P RasmussenDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.
Xiao-Bo ZhongDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.
University of Connecticut · US

Funding

Short- or long-term impacts of drug exposure at early life on drug metabolism, therapeutic efficacy, and drug-induced toxicityR01GM118367 · NIGMS · UNIVERSITY OF CONNECTICUT STORRS · PI ZHONG, XIAO-BO · 2016 to 2019
$1.2M
NIGMS NIH HHS R01 GM118367
6 · The paper itself

Abstract

Precision medicine is a rapidly-developing modality of medicine in human healthcare. Based on each patient׳s unique characteristics, more accurate dosages and drug selection can be made to achieve better therapeutic efficacy and less adverse reactions in precision medicine. A patient׳s individual parameters that affect drug transporter action can be used to develop a precision medicine guidance, due to the fact that therapeutic efficacy and adverse reactions of drugs can both be affected by expression and function of drug transporters on the cell membrane surface. The purpose of this review is to summarize unique characteristics of human breast cancer resistant protein (BCRP) and the genetic variability in the BCRP encoded gene

Indexed as

3′-UTR, 3′-untranslated region5-aza-C, 5-aza-2′-deoxycytidineABCG2, ATP-binding cassette subfamily G member 2ALL, acute lymphocytic leukemiaAML, acute myeloid leukemiaAUC, area under curveBCRPBCRP, breast cancer resistant proteinEpigeneticsFTC, fumitremorgin CGene polymorphismsH3K4me3, histone H3 lysine 4 trimethylationH3K9me3, histone H3 lysine 9 trimethylationH3S10P, histone H3 serine 10 phosphorylationHDAC, histone deacetylaseHIF-1α, hypoxia inducible factor 1 subunit alphaHIV-1, human immunodeficiency virus type-1HMG-CoA, β-hydroxy-β-methyl-glutaryl-coenzyme AMDR1, multidrug resistance 1MDR, multidrug resistancemiRNA, microRNANBD, nucleotide binding domainP-gp, P-glycoproteinPhysiologic factorsPrecision medicineRISC, RNA-induced silencing complexsiRNA, small RNA interferenceSNP, Single nucleotide polymorphismTat, transactivator proteinTKI, tyrosine kinase inhibitor

Identifiers

PMID31384528
PMCPMC6664102
OpenAlexW2909242481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.